| Advancing Innovation in Critical Care | |
Product Licensing PartnershipsOverviewWe intend to continue building our critical care franchise of hospital products by selectively acquiring and developing early and late stage product candidates or products approved for marketing. We seek product licensing deals with larger pharmaceutical companies in the process of refining their own product portfolios and from smaller companies seeking specialist development or commercial collaborations. In evaluating product acquisition candidates, we will continue to seek products that have the potential to alleviate the growing pressures on U.S. hospitals to treat patients more efficiently. In general, we look for:
In making our acquisition decisions, our approach is to:
We believe that all of our products fit the profile set forth above. For each of the in-licensed products (Angiomax, Cleviprex, and cangrelor), we structured the license agreements to include an up-front payment, milestone payments upon marketing and regulatory achievements and royalties on eventual product sales. For products gained through acquisition (CU2010 and oritavancin), deal terms included an up-front payment and contingent payments based on achievement of relevant developmental, regulatory, and commercial milestones. International Distribution PartnershipsThe Medicines Company partners with several companies to market Angiomax outside of the United States. Angiomax is marketed in Europe under the trade name Angiox® (bivalirudin). |
|
| The Medicines Company (Nasdaq: MDCO) | Disclaimer | Copyright ©2009 |
|